The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00856609|
Recruitment Status : Completed
First Posted : March 6, 2009
Results First Posted : January 12, 2018
Last Update Posted : January 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Weight Loss Obesity||Drug: Byetta (exenatide) Behavioral: Weight loss Other: Metabolic Chamber Drug: Placebo||Phase 3|
Obesity can lead to a number of health problems including diabetes, heart disease, stroke, low back pain, fatty liver disease, and osteoarthritis. The medical treatments currently available for obesity are limited. Exenatide is an injectable medication approved for treatment of type 2 diabetes that causes weight loss in some diabetic subjects. The reasons exenatide is thought to cause weight loss include decreased food intake, increased feelings of fullness and nausea. Because levels of a human gut hormone (glucagon like peptide 1) that is similar to exenatide have been shown to be related to resting energy expenditure, it is also possible that exenatide may have effects on a person s metabolism, a.k.a. energy expenditure, but any effect of exenatide on energy expenditure has yet to be evaluated. Even though exenatide is used to treat diabetes, administration of exenatide to non-diabetic lean individuals did not cause frankly low blood sugars.
The primary goal of this study is to investigate the way in which exenatide given twice a day to obese (BMI >= 30 kg/m^2) people without diabetes might lead to weight loss. Because response to weight loss treatment can be highly variable between individuals, we will look at the role of exenatide in changing food intake and energy expenditure as possible explanations for weight loss. We will also assess the safety profile of exenatide in non-diabetic obese people.
This study will involve the use of exenatide or placebo, determined randomly, in obese individuals without diabetes over a 5 week period. The primary measurements will include effects of exenatide on energy expenditure and food intake. We will also look at changes in body fat and the levels of hormones involved in the sensations of hunger and fullness. We will assess if any exenatide-induced changes can predict which individuals lose weight over the 5 weeks. The safety and side effects of exenatide in non-diabetic individuals during this time will also be determined. Findings from this study would help to determine how exenatide works to cause weight loss in people without diabetes, who might benefit most, and would help to improve understanding of why some people respond better to weight loss treatment than others.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||150 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||The Effects of Exenatide (Byetta) on Energy Expenditure and Weight Loss in Non-Diabetic Obese Subjects|
|Study Start Date :||March 3, 2009|
|Actual Primary Completion Date :||September 19, 2016|
|Actual Study Completion Date :||September 19, 2016|
Active Comparator: Exenatide
10 micrograms subcutaneously twice
Drug: Byetta (exenatide)
Exenatide is an injectable medicationBehavioral: Weight loss
Because response to weight loss
Placebo Comparator: Placebo
Other: Metabolic Chamber
The subject stays in the small roomDrug: Placebo
- Energy Intake [ Time Frame: Day 6-7-8 (at baseline) and Day 2-13-14 (3 days after starting study intervention) ]Mean of 3-day food intake change between 3 days (Day 6-7-8) at baseline assessment and 3 days (Day 12-13-14) during the intervention period between the exenatide and placebo groups
- Twenty-four-hour Energy Expenditure [ Time Frame: Day 5 and Day 11 ]Change of twenty-four-hour energy expenditure between at Day 5 at baseline assessment and at Day 11 two days after starting study medication between the exenatide and placebo groups
- Body Weight [ Time Frame: 5 weeks ]Mean decrease between pre- and post-randomization in 5 Weeks between the exenatide and placebo groups.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00856609
|United States, Arizona|
|Phoenix, Arizona, United States, 85014|
|Principal Investigator:||Jonathan Krakoff, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|